Recombinant Bovine Somatotropin vs Brominated Vegetable Oil: which is worse?

What is Recombinant Bovine Somatotropin?

Recombinant bovine somatotropin (rBST) is the synthetic version of bovine growth hormone (BST), naturally produced by the pituitary gland in cattle. The recombinant version is produced using genetically engineered bacteria and is injected into dairy cows to increase milk production by 10-15%. Brand name: Posilac.

What is Brominated Vegetable Oil?

Brominated vegetable oil (BVO) is a food additive created by bonding bromine atoms to vegetable oil (typically soybean oil), creating a denser-than-water compound. When added to citrus-flavored beverages, BVO acts as an emulsifier and weighting agent, keeping citrus flavor oils evenly distributed throughout the drink rather than floating to the surface.

Documented risks

Recombinant Bovine Somatotropin: See recombinant-bovine-growth-hormone-rbgh for full detail. Key concerns: rBST elevates IGF-1 in milk; elevated blood IGF-1 is associated with breast, prostate, and colorectal cancer risk in epidemiological studies. Animal welfare: increased mastitis (up to 25-50% higher rates), lameness, and antibiotic use. The Codex Alimentarius Commission declined to endorse rBST safety MRLs in a historic 33-29 vote. Health Canada rejected rBST approval in 1999 after finding it caused significant animal health problems requiring increased antibiotic use.

Brominated Vegetable Oil: BVO's health concerns center on bromine accumulation in body fat and tissues. Bromine is a halogen related to iodine, and it competes with iodine in the body, potentially disrupting thyroid function—a critical concern since iodine is essential for thyroid hormone synthesis. The FDA-NIH collaborative research directly triggering the 2024 ban found adverse cardiac and thyroid effects in animal studies. This FDA-NIH work, published around 2022–2023, showed effects at dose levels closer to realistic human exposure than previous studies, removing the basis for BVO's safety determination under the Federal Food, Drug, and Cosmetic Act's 'reasonable certainty of no harm' standard. Historical case reports of human toxicity from excessive BVO consumption document bromoderma (skin lesions), memory loss, nerve damage, tremors, and fatigue in individuals consuming large volumes of BVO-containing beverages daily. Two well-documented US cases from the 1970s and 1980s involved bromism (bromine toxicity) from chronic overconsumption. Bromine bioaccumulates in fatty tissues. Long-term sub-clinical accumulation was a concern even before the FDA ban, particularly for heavy consumers of citrus sodas. The EU, Japan, and other countries banned BVO decades ago, making the US one of the last major markets to revoke approval. The FDA issued a proposed rule in November 2023 and a final rule on July 3, 2024, effective August 2, 2024, with compliance deadline August 2, 2025, after which BVO-containing products may not be manufactured for US sale.